nature medicine VOLUME 16 | NUMBER 11 | NOVEMBER 2010 1 3 2 1 T-ALL is an aggressive hematologic tumor resulting from the malignant transformation of T cell progenitors. The TLX1 oncogene is translocated and aberrantly expressed in 5-10% of pediatric and up to 30% of adult T-ALL cases [1] [2] [3] [4] . In addition, TLX3, a closely related TLX family member, is overexpressed as a result of the t(5;14)(q35;q32) translocation in about 25% of pediatric T-ALLs and in 5% of adult T-ALL cases 5 . TLX1 expression defines a distinct molecular group of T-ALL characterized by a differentiation block at the early cortical stage of thymocyte development 2 and a favorable prognosis 1,2,6 . Moreover, TLX1 and TLX3 leukemias seem to constitute a distinct oncogenic group with specific genetic alterations rarely found in non-TLX-induced T-ALLs, including the rearrangement of the NUP214-ABL1 oncogene 7 (a fusion of the gene encoding 214-kDa nucleoporin and c-abl oncogene-1, non-receptor tyrosine kinase) and mutations in the WT1 (encoding Wilms tumor-1 homolog) 8 and PHF6 (encoding PHD finger protein-6) 9 tumor suppressor genes. However, little is known about the specific mechanisms that mediate T cell transformation downstream of TLX1. To address this question, we have used an integrative genomic approach to characterize the transcriptional programs and oncogenic pathways active in human and mouse TLX1-induced leukemia.
T-ALL is an aggressive hematologic tumor resulting from the malignant transformation of T cell progenitors. The TLX1 oncogene is translocated and aberrantly expressed in 5-10% of pediatric and up to 30% of adult T-ALL cases [1] [2] [3] [4] . In addition, TLX3, a closely related TLX family member, is overexpressed as a result of the t(5;14)(q35;q32) translocation in about 25% of pediatric T-ALLs and in 5% of adult T-ALL cases 5 . TLX1 expression defines a distinct molecular group of T-ALL characterized by a differentiation block at the early cortical stage of thymocyte development 2 and a favorable prognosis 1, 2, 6 . Moreover, TLX1 and TLX3 leukemias seem to constitute a distinct oncogenic group with specific genetic alterations rarely found in non-TLX-induced T-ALLs, including the rearrangement of the NUP214-ABL1 oncogene 7 (a fusion of the gene encoding 214-kDa nucleoporin and c-abl oncogene-1, non-receptor tyrosine kinase) and mutations in the WT1 (encoding Wilms tumor-1 homolog) 8 and PHF6 (encoding PHD finger protein-6) 9 tumor suppressor genes. However, little is known about the specific mechanisms that mediate T cell transformation downstream of TLX1. To address this question, we have used an integrative genomic approach to characterize the transcriptional programs and oncogenic pathways active in human and mouse TLX1-induced leukemia.
RESULTS

T-ALL development in TLX1-transgenic mice
To investigate the mechanisms of T cell transformation driven by TLX1, we generated p56 Lck -TLX1 transgenic mice in which the Lck proximal promoter drives expression of TLX1 in T cell progenitors 10, 11 .
TLX1-transgenic mice from three founder lines showed accelerated
The TLX1 oncogene (encoding the transcription factor T cell leukemia homeobox protein-1) has a major role in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL). However, the specific mechanisms of T cell transformation downstream of TLX1 remain to be elucidated. Here we show that transgenic expression of human TLX1 in mice induces T-ALL with frequent deletions and mutations in Bcl11b (encoding B cell leukemia/lymphoma-11B) and identify the presence of recurrent mutations and deletions in BCL11B in 16% of human T-ALLs. Most notably, mouse TLX1 tumors were typically aneuploid and showed a marked defect in the activation of the mitotic checkpoint. Mechanistically, TLX1 directly downregulates the expression of CHEK1 (encoding CHK1 checkpoint homolog) and additional mitotic control genes and induces loss of the mitotic checkpoint in nontransformed preleukemic thymocytes. These results identify a previously unrecognized mechanism contributing to chromosomal missegregation and aneuploidy active at the earliest stages of tumor development in the pathogenesis of cancer. mortality due to the development of lymphoid tumors with a median latency of 27, 32 or 46 weeks, respectively (P < 0.0001) (Fig. 1a) . Tumor-bearing mice showed enlarged thymi populated by immature lymphoblasts and leukemic infiltration of bone marrow and peripheral organs including lymph nodes, spleen, liver and kidneys (Fig. 1b) . Overall, 92% of TLX1-transgenic mice developed tumors at 52 weeks. TLX1-induced leukemias showed high amounts of TLX1 protein (Fig. 1c,d ) and expression of CD3 indicative of a T cell phenotype (Fig. 1e) . Moreover, flow cytometry analysis showed expression of CD4 and CD8 in most tumors (Fig. 1f,g ). In addition, this analysis revealed marked heterogeneity in these leukemias, with 53% of the tumors showing two or more immunophenotypically different cell populations (Fig. 1f) . Finally, TLX1-induced tumors showed clonal expression of a single Tcrb chain in four of five tumors examined and only two Tcrb chains in the remaining sample (Fig. 1h) , indicating that, despite their heterogeneous immunophenotypes, these are monoclonal T cell tumors.
To determine the transcriptional programs activated in mouse TLX1 leukemias, we analyzed the expression profiles of mouse tumors from TLX1-transgenic mice (n = 6) and of T-ALLs generated by retroviral insertional mutagenesis or arising in the context of several T-ALL transgenic and knockout models including Tal1 (encoding T cell acute lymphocytic leukemia-1), Lmo2 (encoding LIM domain only-22) and Olig2 (oligodendrocyte lineage transcription factor-2) transgenics and Tcf3 (encoding transcription factor-3), Trp53 (encoding p53) and Pten (encoding phosphatase and tensin homolog) knockouts (n = 49) (Supplementary Table 1) . Significantly different changes in expression of genes were calculated with the Comparative Marker Selection Genepattern tool 12 using a t test and nonparametric P value calculation (1,000 random permutations). This analysis revealed that TLX1-transgenic tumors are characterized by a distinct gene expression signature, with upregulation of 114 genes and downregulation of 377 (more than twofold change, P < 0.005) (Fig. 2a and Supplementary Table 2) . Moreover, gene set enrichment analysis (GSEA) of human T-ALL samples (n = 82) with these mouse TLX1-signature genes showed significant enrichment in human TLX1 and TLX3 tumors (P < 0.001) (Fig. 2b and 
Supplementary Table 3)
, highlighting the relevance of our mouse model for the analysis of TLX-induced transformation.
Next we decided to explore the effects and mechanistic role of TLX1 expression in T cell progenitors in young TLX1-transgenic mice before the development of T-ALL. Analysis of TLX1-transgenic mice at 3 and 6 weeks of age showed a drastic reduction in thymic size and cellularity compared with littermate controls (Fig. 3a) , but no clear defects in cell proliferation (Fig. 3b) . Flow cytometry analysis of thymocyte differentiation markers in TLX1-transgenic mice and littermate controls showed a defect in T cell development with arrest at the double-negative 2 (DN2) stage of thymocyte differentiation (Fig. 3c) , which was accompanied by a marked increase in apoptosis (Fig. 3d,e) . Consistent with these results, transgenic expression of BCL2 (encoding B cell leukemia/lymphoma-2) in Lck-TLX1, Vav-BCL2 doubletransgenic mice abrogated apoptosis (Fig. 3f) and rescued the defect in thymus size (Fig. 3g) and cellularity ( Fig. 3h) observed in preleukemic TLX1-transgenic mice.
Secondary mutations in the pathogenesis of TLX1-induced T-ALL The 6-to 11-month-long latency in the development of T-ALL in TLX1-transgenic mice and the clonal nature of these tumors prompted us to investigate the presence of cooperating mutations involved in the pathogenesis of TLX1-induced leukemias. Toward this goal, we performed mutation analysis of Notch1 (encoding Notch gene homolog-1) in 25 TLX1-induced tumors and array comparative genomic hybridization (aCGH) in 15 T-ALLs from TLX1-transgenic mice. Activating mutations in NOTCH1 are present in over 50% of human T-ALLs 13, 14 . Similarly, prototypical mutations in Notch1 were present in 3 of 25 (12%) TLX1-induced mouse tumors (Supplementary Table 4 ). Moreover, aCGH analysis revealed the presence of recurrent numerical and structural chromosomal alterations in TLX1-induced leukemias ( Fig. 4a and Supplementary Fig. 1 ). Thus, focal homozygous deletions affecting the Pten tumor suppressor gene were present in 4 of 15 (27%) samples (Fig. 4a, Supplementary Fig. 1 and Supplementary Table 5 ). In addition, immunohistochemical analysis of Pten showed loss of Pten protein expression in 11 of 24 (42%) tumors (Supplementary Fig. 1) . Notably, PTEN deletions, mutations and loss of PTEN protein expression have been reported in 20% of human T-ALLs 15, 16 . Chromosomal deletions involving Trp53 and Ikzf1 (encoding IKAROS family zinc finger-1), which are sporadically mutated and deleted in human T-ALLs 17, 18 , were each detected in one tumor (Fig. 4a, Supplementary Fig. 1 and Supplementary Table 5) . Similarly, a single TLX1-induced T-ALL showed a deletion of the Cdkn2a tumor suppressor locus, which is recurrently deleted in over 70% of human T-ALLs 2 ( Fig. 4a, Supplementary Fig. 1 and Supplementary Table 5 ). In addition, three mouse TLX1-induced T-ALL samples harbored heterozygous deletions in chromosome 12 with a minimally common deleted region containing only the Bcl11b (encoding B cell leukemia/ lymphoma-11B) gene (Fig. 4a-c and Supplementary Table 5) . Moreover, DNA sequence analysis of Bcl11b showed the presence of Bcl11b mutations in 4 of 15 (27%) mouse TLX1-induced T-ALLs (Fig. 4d ,e and Supplementary Table 6), which, together with the three Bcl11b deletions identified in our aCGH analysis, brings the prevalence of Bcl11b alterations in mouse TLX1-induced tumors to 7 in 15 (47%). Notably, mutation analysis of Bcl11b in T-ALL tumors occurring in Pten-knockout mice (n = 6), Trp53-knockout mice (n = 2), Ctnnb1 (encoding catenin (cadherin-associated protein), β1)-transgenic mice (n = 4) or induced by retroviral insertional mutagenesis (n = 9) failed to detect any Bcl11b mutations in these non-TLX1-transgenic tumors (Fisher's exact test, P < 0.001).
Recurrent deletions and mutations in BCL11B in human T-ALL Bcl11b encodes a zinc finger transcription factor with a crucial role in the differentiation and survival of T cell progenitors in the thymus 19, 20 . Given the similarities between our mouse model of TLX1-induced leukemia and human T-ALL, we hypothesized that BCL11B alterations could also be implicated in the pathogenesis of human T-ALL. Most notably, aCGH analysis of human T-ALL samples showed the presence of focal heterozygous deletions encompassing the BCL11B locus in 2 of 69 (3%) T-ALL cases (Fig. 5a ). In addition, mutation analysis of BCL11B in human T-ALL showed the presence of truncating frameshift mutations and missense point mutations in 9 of 71 (13%) cases analyzed (Fig. 5b) . Notably, all six BCL11B missense mutations involved zinc finger domains (Fig. 5b) . One sample showed compound heterozygous BCL11B mutations, whereas the remaining five cases harbored heterozygous BCL11B lesions (Supplementary Table 7) .
Notably, sequence analysis of samples obtained at the time of clinical remission showed the somatic origin of BCL11B mutations in all six cases with available material (Fig. 5c) . Finally, expression analysis of TLX1 or TLX3 in eight T-ALLs harboring mutations or deletions in BCL11B with RNA available showed aberrant expression of these transcription factor oncogenes in five of eight (63%, TLX1 in four, TLX3 in one) of these samples (Supplementary Table 7 ). Altogether, these results identify BCL11B as a tumor suppressor gene recurrently deleted and mutated in human T-ALL.
Interaction between BCL11B and TLX1 in T cell transformation The identification of a high prevalence of Bcl11b mutations and deletions in TLX1-induced tumors suggest a specific genetic interaction between these two genes in T cell transformation. To test whether BCL11B could be a direct transcriptional target of TLX1 in T-ALL, we analyzed the binding of TLX1 to the BCL11B promoter via chromatin immunoprecipitation analysis in ALL-SIL, a human T-ALL cell line expressing high levels of TLX1 as result of the t(10;14)(q24;q11) translocation 21 . This analysis revealed that TLX1 binds the BCL11B promoter (Fig. 5d) . Moreover, siRNA-mediated MPZL2  ADAM19  RASGRP1  IGF2BP3  NR3C1  PLOD2  KCNAB3  CHRNA3  SEC61A1  TFRC  SDC1  TFRC  CLDN10  TFRC  TFRC  STAT5A  SLC6A6  PNN  TRIB2  IKZF1  ETS1  PTP4A2  ZFP82  PKNOX1  DCK  TRP53  SCD2  AHCYL1  EIF4A-PS4  CAPRIN1  DNM2 knockdown of TLX1 in this cell line resulted in transcriptional upregulation of BCL11B (Fig. 5e) , indicating that BCL11B is a direct transcriptional target downregulated by TLX1 in T-ALL.
Aneuploidy in TLX1-induced T-cell transformation
In addition to identifying focal areas of amplification and deletion, our aCGH analysis of mouse TLX1 tumors showed gains and losses of whole chromosomes in most samples analyzed, suggesting a high prevalence of numerical chromosomal abnormalities in these leukemias ( Fig. 4a and Supplementary Table 8 ). Spectral karyotyping analysis confirmed these results and showed the presence of trisomy 15 in three of four TLX1 tumor samples analyzed ( Fig. 6a and Supplementary Table 8) . Overall, 78% (14 of 18) of TLX1-induced leukemias showed chromosomal gains and losses, with 67% (12 of 18) harboring trisomy 15 (alone or in combination with trisomy 17, gain of chromosome Y, monosomy X or hyperdiploidy) ( Fig. 6b and Supplementary Table 8) . Previous in vitro studies have associated TLX1 with alterations in the G2-M cell cycle checkpoint 22 , and forced expression of TLX1 can induce aneuploidy in B cells after disruption of the mitotic spindle 23 . To test the function of the mitotic checkpoint in our TLX1-induced leukemias, we treated TLX1-expressing T-ALL lymphoblasts with paclitaxel, which impairs microtubule remodeling. This analysis revealed that TLX1-transgenic mouse T-ALL lymphoblasts fail to arrest in mitosis following disruption of the mitotic spindle (Fig. 6c) . In contrast, tumors induced by TAL1, TAL1 and LMO1 (encoding LIM domain only-1), TAL1 and LMO2 or the NUP214-ABL1 T-ALL oncogene showed a marked accumulation of cells in mitosis after paclitaxel treatment ( Fig. 6c and Supplementary Fig. 2) . We obtained similar results with nocodazole, which disrupts tubulin polymerization (Fig. 6c) , and BrdU incorporation analysis verified that TLX1-expressing mouse tumors proliferate and fail to arrest in M phase after disruption of the mitotic spindle (Supplementary Fig. 3) .
The acquisition of chromosomal instability may represent an early event in the pathogenesis of cancer 24 . To investigate the specific mechanisms involved in the earliest stages of TLX1-induced transformation, we performed microarray gene expression analysis of sorted preleukemic DN2 cells from 3-week-old mice. We calculated significant differences in gene expression by Comparative Marker Selection Genepattern tool 12 as described above. This analysis revealed marked differences in gene expression in TLX1-transgenic thymocytes and DN2 cells from normal littermate controls, with 175 genes upregulated and 138 genes downregulated in TLX1-expressing cells (a fold change of >1.5, P < 0.005) (Supplementary Table 9 ). Next, and to specifically address the role of direct TLX1 target genes in T cell transformation, we performed chromosome immunoprecipitation (ChIP)-on-chip analysis of TLX1 in ALL-SIL cells. In these experiments, TLX1 chromatin immunoprecipitates were hybridized to human proximal promoter arrays and analyzed with ChIP-on-chip significance analysis to identify high-confidence TLX1 direct target genes 25 . This analysis identified 5,549 promoters bound by TLX1 with a significance cutoff of P < 0.0001 (Supplementary Table 10) . Integration of these ChIPon-chip results with the gene expression signature associated with aberrant expression of TLX1 in T cell progenitors revealed a marked enrichment of TLX1 direct-target genes involved in mitosis (P < 0.001) (Supplementary Table 11 ) downregulated in TLX1-expressing DN2 (Fig. 6d) and DP ( Supplementary Fig. 4 ) preleukemic cells. Notably, these included CHEK1, a key regulator of the mitotic spindle checkpoint and one of the genes most consistently downregulated in both mouse and human TLX-induced leukemias (Supplementary Tables 2  and 3) . Consistent with these results, knockdown of TLX1 in ALL-SIL cells resulted in transcriptional upregulation of CHEK1 (Fig. 6g) , and pharmacologic inhibition of CHEK1 (Gö6976, 1,000 Mm) 26 in human T-ALL cell lines abrogated the activation of the mitotic checkpoint upon treatment with paclitaxel ( Supplementary Fig. 5) . These results suggest a mechanistic role of TLX1 in the control of cell cycle checkpoint genes at the earliest stages of T cell transformation.
To test whether TLX1 expression can induce a defective mitotic checkpoint phenotype in preleukemic cells, we isolated viable thymocytes from TLX1 and BCL2 double-transgenic mice and compared them with cells obtained from BCL2-transgenic controls. This experiment showed a marked defect in the activation of the mitotic checkpoint after paclitaxel treatment in TLX1-and BCL2-transgenic preleukemic cells compared with BCL2 controls (Fig. 6h) . The polyclonal nature of TLX1-and BCL2-transgenic preleukemic cells was verified by RT-PCR analysis of Tcrb expression (Supplementary Fig. 6 ).
TLX1 + BCL2 BCL2
Overall, these results demonstrate that the impaired control of the mitotic checkpoint in TLX1-transgenic mice is an early event in tumor formation that precedes clonal selection in T cell transformation. The presence of secondary mutations and numerical chromosomal alterations in TLX1 tumors raises the possibility that TLX1 overexpression might be involved in tumor initiation by promoting genomic instability but less so in maintaining the tumor phenotype. To determine whether TLX1 is indeed required for not only tumor initiation but also tumor maintenance, we analyzed cell proliferation and survival in ALL-SIL cells upon siRNA knockdown of TLX1. This analysis showed reduced cell numbers and increased apoptosis in T-ALL lymphoblasts electroporated with TLX1 siRNAs compared with controls (Supplementary Fig. 7) . These results suggest that TLX1 overexpression contributes to induce increased proliferation and survival in established T-ALL lymphoblasts.
Chromosomal alterations in human TLX-induced leukemias Overall, the results described above support a direct mechanistic role for TLX1 in the induction of chromosomal missegregation, suggesting that similar mechanisms may operate in the pathogenesis of human leukemias. Most notably, and consistent with this hypothesis, the TLX1-positive ALL-SIL cell line showed a selective defect in the mitotic checkpoint (Supplementary Fig. 2 ). In addition, karyotype analysis of a series of 57 well-characterized pediatric T-ALLs 2 showed a higher frequency of aneuploid karyotypes (8 of 13, 62%) in TLX1-overexpressing and TLX3-overexpressing human T cell tumors compared with other genetic subgroups of T-ALL (5 of 44, 11%) (Fisher's exact test, P < 0.001) (Supplementary Table 12) . Moreover, analysis of an independent series of 229 T-ALLs showed a marked predominance of numerical chromosomal abnormalities in TLX1-overexpressing and TLX3-overexpressing T-ALLs (aneuploid to pseudodiploid karyotype a r t i c l e s 1 3 2 6 VOLUME 16 | NUMBER 11 | NOVEMBER 2010 nature medicine ratios: 6:1 for TLX1 tumors; 10:10 for TLX3 leukemias and 24:63 for non-TLX T-ALLs; Fisher's exact test P < 0.004 for TLX1 versus non-TLX; P < 0.05 for TLX3 versus non-TLX and P < 0.003 for TLX1-overexpressing or TLX3-overexpressing T-ALLs versus leukemias expressing neither TLX1 nor TLX3) (Supplementary Table 13 ).
DISCUSSION
TLX1 has a central role in the pathogenesis of T-ALL. However the elucidation of the specific mechanisms that mediate T cell transformation downstream of TLX1 has been hampered by our limited understanding of the direct transcriptional targets controlled by TLX1 in human leukemia and by the lack of an animal model of TLX1-induced T-ALL. Thus, early attempts to generate a mouse model of TLX1-induced T-ALL using the Lck proximal promoter were unsuccessful and only a mouse transgenic line ectopically expressing TLX1 under the control of the immunoglobulin heavy chain (IgH) promoter and enhancer sequences in B-lineage cells showed the development of mature marginal zone B-cell lymphomas 27 .
Here we report the development of clonal immature T cell tumors in Lck-TLX1-transgenic mice. Notably, mouse TLX1-induced T-ALLs are highly related to human TLX1-overexpressing and TLX3-overexpressing T-ALLs in their clinical presentation and gene expression signatures. The extended latency in the development of leukemia in this model and the clonal nature of TLX1-induced tumors suggest that TLX1 overexpression in the thymus is not sufficient for malignant transformation of T cell progenitor cells. This idea is further supported by our identification of recurrent cooperating mutations and chromosomal abnormalities in mouse TLX1-induced leukemias. Most notably, TLX1-induced tumors harbored recurrent alterations in oncogenes (Notch1) and tumor suppressor genes (Pten, Cdkn2a) frequently mutated in human T-ALL [13] [14] [15] 28 . In addition, this analysis revealed the presence of recurrent mutations and deletions centered on the Bcl11b locus in 47% of mouse TLX1-induced tumors analyzed. Given these results, we hypothesized that BCL11B could be a tumor suppressor in human leukemia and identified recurrent deletions and mutations in this gene in 16% of human T-ALLs. Notably, most BCL11B alterations found in mouse TLX1-induced tumors and in human T-ALLs were heterozygous, and loss of one copy of Bcl11b in mice accelerates the development of thymic lymphomas after γ irradiation or in Trp53-heterozygous mice without loss of the wild-type Bcl11b allele 29 . Finally, ChIP and expression analysis showed that BCL11B is a direct transcriptional target downregulated by TLX1 in T-ALL. The model that emerges from these results is that aberrant expression of TLX1 partially downregulates the BCL11B tumor suppressor gene during T cell transformation, and that this negative transcriptional regulatory axis is fixed and reinforced by secondary genetic alterations in the BCL11B locus acquired during tumor progression. Notably, PHF6 and WT1, two additional tumor suppressor genes frequently mutated in TLX1-induced T-ALL, are also among the TLX1 targets identified in our ChIP-on-chip analysis (Supplementary Table 10) , suggesting that this model could also broadly apply to other TLX1-target tumor suppressor genes.
Perhaps the most noteworthy finding in our mouse model of TLX1-induced leukemias was the presence of a very high incidence of numerical chromosomal alterations in these tumors, indicating that Mechanistically, analysis of TLX1 direct target genes in the context of TLX1 preleukemic thymocytes revealed that multiple TLX1 direct target genes involved in mitosis and chromosomal segregation are downregulated in preleukemic T cell progenitor cells isolated from TLX1-transgenic mice. Among these, CHEK1, a crucial checkpoint regulator, is downregulated in mouse and human TLX-induced leukemias and could have a particularly prominent role in the loss of the mitotic checkpoint downstream of TLX1. However, it would be misleading to attribute the induction of aneuploidy by TLX1 to the dysregulation of a single gene, as multiple transcripts with prominent roles in mitosis seem to be controlled by TLX1 in T cells. In addition, a transcription-independent effect of TLX1 in the control of cell cycle via interaction with the PP2A phosphatase has been proposed 22 .
Overall, our results mechanistically link aberrant expression of TLX1 with the development of chromosomal instability at the earliest stages of T cell transformation and illustrate the power of integrative genomic analyses of mouse and human tumors to elucidate basic mechanisms and oncogenic pathways involved in tumor initiation and disease progression.
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